Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts Cut Sun Forecasts After New Halol Site Faults

Executive Summary

Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.

You may also be interested in...



Sun’s Key Halol Plant Flunks FDA Inspection Again

The US FDA has flagged more issues at Indian firm Sun Pharma’s largest manufacturing plant in Halol but analysts are hoping the infractions are minor and that the Indian facility will get the regulatory green light soon, ending a blacklist on the factory supplying new products to the US.

FDA To Lift Ban On Ranbaxy Plant; Good News For Sun Compliance Push?

A US FDA ban on Sun Pharma’s Mohali site, a legacy Ranbaxy facility, is set to be lifted, marking a significant uptick in Sun’s compliance efforts and raising hopes of momentum at the Indian firm’s other tainted facilities.

How Indian Firms Are Rebooting For Quality Transformation

Against a backdrop of heightened regulatory scrutiny of manufacturing sites and processes, the heads of five top Indian firms told a recent forum in Mumbai how they are “rebooting” quality compliance and culture within their organizations. Tangible and intangible results are beginning to show but there is a long road ahead.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel